Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (Po.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-g) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.
T he potential benefits of immunotherapy as an adjunct to conventional forms of cancer treatment are under active investigation. [1] [2] [3] [4] Activated CTLs capable of recognizing and destroying cancer cells are generated in immunized mice, and patients. The immunity is directed toward unique MHC class I-restricted tumor-associated antigens (TAAs) expressed by the malignant cells. [5] [6] [7] [8] A major constraint of this form of treatment, however, is the inability of the immune system to effectively destroy large, established neoplasms. An immunotherapeutic strategy, therefore, that could be applied to patients with minimal residual disease after primary therapy could have significant benefits. However, obtaining sufficient quantities of tumor tissue to prepare vaccines in patients who are in clinical remission is not always possible.
Numerous immunization strategies involving dendritic cells (DCs) are in various stages of investigation. Immunotherapeutic vaccines have been prepared by ''feeding'' bone marrow-derived DCs, tumor cell lysates, lysate fractions or apoptotic cell bodies from tumor cells. 9 Vaccines were also prepared by fusing allogeneic DCs with tumor cells 10 and by the transfer of RNAs from tumor cells into DCs. 11 In some instances, cytokines such as IL-2 have been administered along with DC-based vaccines to further augment the cells' immunotherapeutic properties. 12 Certain of these treatment strategies are now in early clinical trials. When successful, the immunizations resulted in the activation of immunity toward the malignant cells. Normal cells of the body were spared. Primary class I and class II-restricted T-cell responses developed in experimental animals and patients immunized with such cellular vaccines. In some instances, significant clinical responses were observed. 13 There are relatively few reports describing the use of vaccines for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN). [14] [15] [16] Current treatment is dependent primarily on surgery, radiation and chemotherapy, in various combinations and schedules. Despite improvements in surgical technique, the development of new chemotherapeutic drugs, and enhanced radiation methods, the overall survival of patients with metastatic SCCHN has remained essentially unchanged. In part, the lack of successful immunotherapeutic approaches in the treatment of patients with the disease may be a reflection of the fact that few TAAs presented by SCCHN have been identified. Other strategies that require relatively large amounts of tumor tissue to prepare the vaccine may restrict treatment to patients with advanced disease.
Tumor antigens including antigens expressed by SCC are the products of mutant/dysregulated genes in the malignant cells, which differ from the homologous genes in nonmalignant cells of the tumor-bearing host. They are weakly immunogenic in the sense that they fail to induce antitumor immune responses that are capable of controlling tumor growth. We reasoned that effective anti SCC immune responses might develop if the antigens were expressed by antigen-presenting cells.
Here, we report a new alternative approach that does not require the identification of TAAs or the establishment of a tumor cell line. It enables the vaccine to be prepared from microgram amounts of tumor tissue. The approach we used is an extension of classic studies indicating that both the genotype and the phenotype of one cell type can be stably altered by transfer of genomic DNA from another. [17] [18] [19] [20] Since the transferred genes are expressed as protein by the recipient cells, the vaccine could be prepared from microgram amounts of tumor tissue. We find that a vaccine for SCC could be prepared by transfer of sheared genomic DNA-fragments (25 kb) from SCC into syngeneic bone marrow-derived DCs. Robust cell-mediated immunity directed toward the SCC was induced in mice immunized with the transfected cells, which resulted in improved survival.
Materials and methods

Experimental animals and tumor cell lines
Pathogen-free DBA/2J female mice 8 to 10 weeks old were from the Jackson Laboratory (Bar Harbor, ME). The animals, between 10 and 14 weeks old when used in the experiments, were maintained according to NIH Guidelines for the Care and Use of Laboratory Animals (UIC Animal Protocol Number 04-067). KLN205 cells, a squamous carcinoma cell line derived from a lung neoplasm that arose in a DBA/2 mouse, were from the Division of Cancer Treatment, Diagnosis and Centers (Frederick, MD) (CRL1453). The cells were maintained by serial passage in histocompatible DBA/2J mice, or at 371 in a humidified 7% CO 2 /air atmosphere in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY) supplemented with 10% heat inactivated fetal bovine serum (FBS) (Sigma, St Louis, MO) and antibiotics (Gibco BRL) (growth medium). B16 cells, a melanoma cell line derived from a neoplasm arising in a C57BL/6 mouse, were from the American Type Culture Collection (ATCC, Bethesda, MD) (CRL-6263). Like KLN205 cells, the melanoma cells were maintained in vitro in growth medium or by serial passage in syngeneic C57BL/6J mice.
Isolation of bone marrow-derived dendritic cells (DCs)
DCs were obtained from the bone marrows of DBA/2J mice, according to the method described previously. 21 In brief, femurs and tibiae of DBA/2J mice were removed and the marrows were flushed with ice-cold DMEM using a syringe attached with a 0.45 mm needle. Larger cell clusters were dissociated by gentle pipetting and the cell suspension was filtered through a 70 mm nylon cell strainer (Becton Dickinson, Franklin Lakes, NJ). Red blood cells were lysed with a lysing solution of NH 4 Cl (0.15 M), KHCO 3 (1 mM) and EDTA (0.1 mM). Afterward, the bone marrow cells were suspended in growth medium. The number of cells in suspension was adjusted to 2 Â 10 5 /ml and 10 6 cells were added to individual wells of six-well plates. The cells were cultured at 371 in a humidified 7% CO 2 /air atmosphere in growth medium supplemented with 1000 U/ml GM-CSF and 1000 U/ml IL-4 (Sigma, St Louis, MO). Equivalent quantities of GM-CSF and IL-4 were added on days 4 and 7. On day 8, the cells were activated by additional pipetting. After 1 day, the nonadherent, proliferating maturing DCs were harvested and suspended in 2-4 ml of growth medium at 371. The DCs were recovered by density gradient centrifugation at 1200 Â g for 20 min at room temperature (RT) in 14.5% (w/v) Nycodenz (Sigma) in growth medium containing 10% FBS. The cells at the interface were collected and washed with growth medium before they were used in the experiments. As judged by double staining with FITC labeled CD11c and PE labeled MHC class II (1-A d ) mAbs (Pharmingen, San Diego, CA), 7575% of the cells were DCs. At least 99% of the cells were viable (0.4% trypan blue staining) (Gibco, Grand Island, NY) at the time they were used in the experiments.
DNA isolation
Unfractionated genomic DNA was isolated from KLN205 squamous carcinoma cells and, for use as a control, from B16 melanoma cells, using DNeasy isolation kits (Qiagen, Valencia, CA), according to the manufacturer's instructions. In brief, 5 Â 10 6 actively proliferating KLN205 (or B16) cells in growth medium were centrifuged at 300 Â g for 5 minutes. The cell pellet was re suspended in 200 ml PBS, followed by the addition of 400 mg RNase A and incubation at RT for 2 minutes. After incubation, 12 mAU proteinase K and 200 ml lysis buffer containing guanidine HCl was added, followed by further incubation at 701 for 10 minutes. In total, 200 ml of 100% ethanol was added and, after mixing, the extracted DNA was loaded onto a DNeasy spin column. The DNA was eluted after two washes with buffer. The A 260 /A 280 ratio of the isolated DNA was greater than 1.8 in each instance. The genomic DNA was isolated and analyzed by electrophoresis in 1% agarose gels. Afterward, the gels were stained with ethidium bromide. 0 -end labeling of sheared genomic DNA with FITC and transfection of the DCs As a means of determining the proportion of cells that took up DNA from the malignant cells, free 3 0 hydroxyl residues of DNA-fragments were labeled with biotinylated nucleotides and then transfected into the DCs. Specific binding of streptavidin-conjugated FITC to the labeled fragments was detected in a FACS. A Flow TACS Apoptosis Detection kit (R and D Systems, Minneapolis, MN, Cat #TA5354) was used, following the directions of the supplier. In brief, 30 mg of sheared genomic DNA fragments (approximately 25 kb) from KLN205 cells in 200 ml reaction buffer were added to 1 ml of terminal deoxynucleotidyl transferase, 1 ml of biotinylated dNTP mixture, 1 ml 50 Â Mn 2 þ and 1 ml TdT enzyme. The reaction mixture was incubated at 371 for 30 minutes after which 1 ml of streptavidin-conjugated FITC was added. The mixture was incubated at RT in the dark for 10 minutes before it was used to transfect the DCs. The labeled DNA in 1.25 ml Opti-MEM was mixed with 60 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA) diluted with 1.25 ml Opti-MEM. The DNA-lipofectamine mixture was then added dropwise to the DCs, followed by incubation at 371 for 3 hours in a 7% CO 2 /air atmosphere. The transfected DCs were incubated under standard cell culture conditions for 5 days, washed and analyzed by FACS for fluorescence, using the procedure described below.
Transfection of DCs with a plasmid DNA specifying green fluorescent protein (GFP)
To determine if the transferred DNA was expressed as protein, 1 Â 10 6 bone marrow-derived DCs were transfected with 1 mg plasmid DNA (pTracer-CMV2; Invitrogen, Carlsbad, CA) specifying GFP. In total, 1 mg of pTracer-CMV2 in 1.25 ml Opti-MEM was mixed with 60 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA) diluted in 1.25 ml Opti-MEM. The DNA-Lipofectamine mixture was then added dropwise to the DCs, followed by incubation at 371 for 3 hours in a 7% CO 2 /air atmosphere. After 5 days, the transfected cells were analyzed for specific fluorescence in a FACS.
Preparation of the vaccine: transfection of DCs with sheared genomic DNA fragments from small numbers of KLN205 cells
The vaccine was prepared by transfer of genomic DNAfragments from KLN205 cells into bone marrow-derived DCs from DBA/2J mice. The DCs were washed two times at RT with Opti-MEM medium (Gibco, BRL, Grand Island, NY). Afterward, 5 Â 10 6 DCs/ml in 2.5 ml DMEM were added to 60 mm Petri dishes (Falcon). In total, 50mg sheared (25 kb) genomic DNA-fragments from KLN205 cells in 1.25 ml Opti-MEM were mixed with 60 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA) diluted in 1.25 ml Opti-MEM. The DNA-Lipofectamine mixture was then added dropwise to the DCs, followed by incubation at 371 for 3 hours in a 7% CO 2 /air atmosphere. The cells were washed with Opti-MEM and then resuspended in the same medium for use in the experiments.
Immunofluorescent staining and cytofluorometric measurements
Quantitative immunofluorescence measurements were used to detect the presence of FITC in DCs transfected with FITC-labeled DNA from KLN205 cells. An analogous assay was used to detect the presence of GFP in cells transfected with pTracer-CMV2, using the method described above. The measurements were performed in an Epic V flow cytofluorograph (Coulter Electronics, Hialeah, FL) equipped with a multiparameter dataacquisition and display system (MDADS). For the analysis, single-cell suspensions were prepared from plastic-adherent monolayer cultures dissociated with 0.1 mM EDTA in PBS. 1 Â 10 6 DCs were washed with PBS and incubated with FITC-labeled CD11c, CD 86, CD21/35 mAbs, or with PE-labeled CD11b, CD40, and CD 80 mAbs. Immunofluorescent staining with FITCconjugated mAbs for MHC class II determinants (1-A d ) was used to determine the proportion of DCs in the cell suspensions. (All mAbs were from Pharmingen, San Diego, CA.) After incubation for 30 minutes on ice, the cells were washed and analyzed by FACS. One-parameter fluorescence histograms were generated by analyzing at least 1 Â 10 4 cells in each instance. Background staining was determined by substituting cells incubated with FITC-conjugated mouse isotype-specific IgG2a serum alone for cells incubated with the specific FITC-conjugated antibodies.
Mouse interferon gamma (IFN-g) enzyme-linked immuno spot (ELISPOT) assays
ELISPOT IFN-g assays were used to detect the presence of spleen cells responsive to KLN205 cells in mice immunized with DCs transfected with DNA from the squamous carcinoma cells. Responder (R) spleen cells from DBA/2J mice immunized with the transfected cells were added into individual wells (1 Â 10 6 cells per well in 0.2 ml growth medium) of 96-well ELISPOT IFN-g plates (B-D Pharmingen, ELISPOT Mouse IFN-gamma Set (Cat #551083) coated with 100 ml of the capture Ab (5 mg/ ml in PBS). Stimulator (S) KLN205 cells were then added at a R:S ratio of 10:1. After 18 hours incubation at 371, the cells were removed by washing with PBS-Tween (0.05%). Detection antibody (2 mg/ml) was added to each well. The plates were then incubated for 2 hours at RT and the washing steps were repeated. Afterward, streptavidin-peroxidase, (Streptavidin-HRP, 5 mg/ml) was added to the individual wells and the plates were washed four times with PBS-Tween and two times with PBS. In total, 100 ml of aminoethylcarbazole staining solution was added to each well to develop the spots. The reaction was stopped after 4-6 minutes with deionized water. The spots were counted using computer-assisted image analysis (ImmunoSpot Series 2 analyzer: Cellular Technology Limited, Cleveland, OH).
Detection of cells cytolytic toward KLN205 cells in the spleens of mice immunized with DC/KLN cells by assay with methylthiazoyl tetrazolium salt (MTS)
A Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI) was used to measure spleen cell-mediated cytotoxicity in mice immunized with the transfected DCs. The number of viable cells was measured by MTS, which is bioreduced by cells into a formazan product that can be detected at 490 nm absorbance. Effector cells (purified from the spleens by Histopaque (Sigma) density gradient and the removal of macrophages by adherence) from immunized mice were cocultured with mitomycin C-treated (50 mg/ml for 45 min) KLN205 target cells. The mixed cell cultures were incubated for 18 hours at a 30:1 effector:target cell ratio. Afterward, the nonadherent cells were removed, washed and viable KLN205 cells were added at various E:T ratios for 4 hours at 371 in a 7% CO 2 /air atmosphere (Experimental group). Control wells containing cells alone were treated with 2% Triton-100 to cause total lysis of the cells (Negative group). Positive control wells (KLN cells alone) did not receive the effector cells. In total, 20 ml of MTS and 1 ml of phenazine methosulfate (PMS), an electron coupling reagent, were mixed and added to each well, followed by incubation at 371 for 1-4 hours at 371 in a 7% CO 2 /air atmosphere after which the absorbance was read. % Specific lysis was calculated from the absorbance using the formula:
positive control À experimental group positive control À negative control Â100
Detection of spleen cell-mediated cytotoxicity by 51 Cr-release assays
Spleen cell-mediated cytotoxicity directed toward KLN205 cells was also determined in a standard 51 Crrelease assay. Suspensions of spleen cells from mice in the experimental and control groups were prepared and the nucleated cells were isolated by histopaque density gradient. The cells were cocultured for 5 days with mitomycin C-treated (50 mg/ml for 45 min) KLN205 cells. The ratio of effector cells:KLN205 target cells ¼ 30:1. Afterward, the nonadherent cells were collected and cocultured with 51 Cr-labeled KLN205 cells. For labeling, 5 Â 10 6 KLN205 cells were incubated at 371 with 51 Cr (Amersham) for 1.5 hours and washed with DMEM before the cells were added to the cell cultures. The culture supernatants were recovered 5 hours later and the radioactivity was determined in a counter using biodegradable scintillation fluid (Research Products International Corp., Palatine, IL). The maximum release of isotope was determined by measuring the release from an equivalent number of labeled tumor cells treated with a cell lysing solution (2% Triton X-100).
The % specific isotope release was calculated from the formula:
experimental 51 Cr-release À spontaneous 51 Cr-release maximum 51 Cr-release À spontaneous 51 Cr-release Â100
Statistical analysis
Kaplan-Meier log rank analysis was used to determine the statistical significance of the differences between the survival of mice in the experimental and control groups. The Student's t-test was used to determine the statistical significance of the ELISPOT, MTS and 51
Cr-release assays. Po .05 was considered significant.
Results
Sheared genomic DNA-fragments from KLN205 squamous carcinoma cells were used to transfect bone marrow-derived DCs from syngeneic DBA/2J mice Gel electrophoresis of genomic DNA from KLN205 cells (1% agarose; stained with ethidium bromide) recovered from the DNA-isolation columns revealed the presence of predominantly 25 kb fragments (Fig 1) . To facilitate DNA uptake and, at the same time, to preserve controlling elements governing gene expression, the size of the DNA-fragments was not reduced further at the time they were added to the cultures of DCs.
The proportion of DCs that took up DNA from KLN205 cells Flow cytometric analysis was used to determine the proportion of the DCs that took up DNA from KLN205 cells. DNA-fragments used for the transfection were endlabeled with FITC before they were added to the DCs. Lipofectamine 2000 was used to aid DNA uptake. At 5 days after the addition of the DNA-fragments to the DCs, the cells were analyzed in a FACS for the presence of labeled cells. The results (Fig 2a) To determine if transferred genes were expressed as protein by the DCs, 1 mg of plasmid DNA specifying GFP was transfected into bone marrow-derived DCs. After 5 days, the DCs were analyzed in a FACS for expression of GFP. As indicated (Fig 2b) (Fig 3a) and bar graphs (Fig 3b) .
Thus, the bone marrow-derived DCs used in the experiments expressed various membrane-associated determinants characteristic of activated cells. Approximately 80% of cells used as recipients of DNA from KLN205 cells expressed activation markers. Transfection with DNA from KLN205 cells had no significant effect on the expression of these determinants.
Immunization of DBA/2J mice with DCs transfected with DNA-fragments from KLN205 cells (DC/KLN) prolonged the survival of mice with SCC
The immunogenic properties of the transfected DCs were investigated in DBA/2J mice, highly susceptible to the growth of the syngeneic KLN205 cells. Approximately 1 Â 10 6 DC/KLN cells in 0.2 ml serum-free medium were injected intravenously (i.v.) three times at weekly intervals into naı¨ve DBA/2J mice. At 1 week after the last injection, the mice received a s.c. injection of 1 Â 10 6 viable KLN205 cells. As controls, other naive mice were injected according to the same schedule with equivalent numbers of nontransfected DCs, with growth medium, or, as a specificity control, with DCs transfected with DNA from an immunologically non-crossreactive tumor (B16 melanoma; DC/B16 cells). As indicated (Fig 4) , mice in the group injected with DC/KLN cells followed by the challenging injection of KLN205 cells survived significantly (Po.001) longer than mice in any of the other groups, including mice injected with DC/B16 cells (8879.7 days and 61.373.0 days respectively). Six out of 22 mice in the group injected with DC/KLN cells appeared to have rejected the KLN205 cells. They were tumor-free for more than 164 days. Without further immunizations, the surviving mice were rechallenged by two subsequent injections at weekly intervals of 1 Â injected s.c. with 1 Â 10 6 KLN205 cells. After 1 week, the mice received the first of three i.v. injections at weekly intervals of 1 Â 10 6 DC/KLN cells. As controls, the same protocol was followed except that the mice were injected with KLN205 cells, followed by i.v. injections with an equivalent number of DC/B16 cells, or the mice were injected with KLN205 cells alone. The results (not presented) indicated that the survival of tumor-bearing mice injected with DC/KLN cells was significantly (Po.05) prolonged relative to that of mice in either of the control groups. The survival naı¨ve mice injected with KLN205 cells alone, or of mice injected with KLN205 cells, followed by DC/B16 cells were not significantly different from each other.
Immunization of DBA/2J mice with DC/KLN cells resulted in the generation of spleen cells responsive to KLN205 cells ELISPOT IFN-g assays were used to detect the presence of cells responsive to KLN205 cells in the spleens of mice immunized with the transfected DCs. In the experiment, DBA/2J mice were injected i.v. three times at weekly intervals with DC/KLN cells. At 1 week after the last injection, spleen cells from the immunized mice were coincubated with KLN205 cells, followed by the ELI-SPOT IFN-g assay. As a control, DCs from DBA/2J mice were transfected with DNA from B16 cells, an antigenically non-crossreactive melanoma cell line (DC/B16). Afterward, spleen cells from mice immunized with DC/ B16 cells were coincubated with KLN205 cells before the ELISPOT IFN-g assays were performed. As indicated (Fig 5) , the number of spots in the group immunized with DC/KLN cells was significantly (Po.01) higher than the number of spots in the group immunized with DC/B16 cells (Fig 5a) .
To determine if the presence of an established tumor of KLN205 cells affected the number of responsive spleen cells, DBA/2J mice were injected with KLN205 cells 7 days after the mice received the three i.v. injections at weekly intervals of DC/KLN cells or, as a control, with an equivalent number of DC/B16 cells. At 77 days after the injection of KLN205 cells, spleen cells from the immunized mice were tested by ELISPOT IFN-g assays (Fig 5a) . As for tumor-free mice immunized with DC/ KLN cells, the mice received the three i.v. injections at weekly intervals of DC/KLN cells or, as a control, with an equivalent number of DC/B16 cells (Fig 5b) . At 1 week after the last immunization, spleen cells from the immunized mice were tested by ELISPOT IFN-g assays. The number of spots from the group of mice immunized with DC/KLN cells was significantly higher than the number of spots from mice immunized with DC/B16 cells. The number of spots in the group with SCC immunized with DC/KLN cells was equivalent to the number of spots in tumor-free mice immunized with the same cellular vaccine. The presence of tumor did not affect the spleen cell response to the vaccine.
Immunization of DBA/2J mice with DC/KLN cells stimulated the generation of cell-mediated immunity toward KLN205 cells
MTS and
51 Cr-release assays were used to detect the presence of spleen cells in mice immunized with the transfected DCs that were cytotoxic toward KLN205 cells. DBA/2J mice were injected i.v. three times at weekly intervals with 1 Â 10 6 DC/KLN cells. At 1 week after the last injection, spleen cells from the injected mice were coincubated for 18 hours with (mitomycin C-treated) KLN205 cells. Afterward, the cells were restimulated by coculture for 4 hours at 371 with viable KLN205 cells. As controls, the same protocol was followed except that the mice were injected with an equivalent number of nontransfected DCs, or the mice were not injected. At the end of the incubation, MTS reagents were added to the cell mixtures and the cytotoxic effects of the cells were determined. The results (Fig 6a) Days after the injection of KLN205 cells DC/B16 (7) DC/KLN (22) DC (9) Naive (10) * p<0.001 Figure 4 Survival of DBA/2J mice injected with DC/KLN cells followed by a challenging injection of KLN205 cells. Naïve DBA/2J mice received three i.v. injections at weekly intervals of 1 Â 10 6 DC/ KLN cells. At 1 week after the last injection, the mice were injected s.c. with 1 Â 10 6 viable KLN205 cells. As controls, the same protocol was followed except that the mice were injected with nontransfected DCs, with DCs transfected with DNA from an unrelated tumor (B16 melanoma) or the mice were not injected before the injection of 6 viable KLN205 cells. After 77 days, the mice were killed and the spleens were removed. Cells from the spleens of the immunized mice were coincubated for 18 hours with KLN205 cells before they were tested in ELISPOT-IFN-g assays for the presence of reactive cells (Ratio of spleen cells to KLN205 cells ¼ 10:1). As a control, the same procedure was followed except that the mice were immunized with DC/B16 cells, a non-crossreactive melanoma cell line, before they were injected with KLN205 cells. Immunity to squamous carcinoma with transfected DCs IS ug O-Sullivan et al obtained in 51 Cr-release cytotoxicity assays. Spleen cells from DBA/2J mice injected with DC/KLN cells as described were coincubated for 5 days with (mitomycin C-treated) KLN205 cells. Afterward, 51 Cr-labeled KLN205 cells were added for 4 hours before the specific release of isotope was determined. The results (Fig 6b) indicated that the specific 51 Cr-release in the group coincubated with spleen cells from mice injected with DC/KLN cells was significantly higher than those of groups coincubated with spleen cells from mice injected with nontransfected DCs or from naı¨ve mice (Po.05).
Thus, both in vivo and in vitro assays demonstrated the immunogenic properties of DCs transfected with genomic DNA-fragments from KLN205 cells against the highly malignant squamous carcinoma cells.
Discussion
Immunity to a highly aggressive squamous carcinoma was generated in mice immunized with syngeneic activated DCs transfected with genomic DNA-fragments from squamous carcinoma cells.
We hypothesized that an array of weakly immunogenic TAAs would be expressed in a highly immunogenic form by the transfected DCs, and that immunization of mice susceptible to the growth of the SCC with the transfected cells would induce the antitumor immune response. Previously identified TAAs may be only several representations of a large number of different tumor antigens expressed by the malignant cells. A major advantage of this approach is that the vaccine could be prepared from microgram quantities of tumor tissue. We routinely used 50 mg of DNA derived from 2 Â 10 7 cells, equivalent to a tumor of approximately 6 mm. The ability to prepare a vaccine from quite small amounts of tumor tissue raises the possibility that SCCHN patients with minimal residual disease after primary therapy can receive immunotherapy. Large, bulky tumors are often immunosuppressive and unresponsive to cytotoxic effects of the immune system.
The immunity in mice injected with the transfected DCs was sufficient to deter tumor growth. In some instances, the immunized mice rejected the squamous carcinoma cells and survived indefinitely. The immunity was specific. Immunization of mice with DCs transfected with DNA from B16 cells, an immunologically noncrossreactive melanoma cell line, failed to induce immunity to the SCC, consistent with the expression of unique TAA by the transfected cells. Spleen cells from mice immunized with the DNA-based vaccine were cytotoxic toward the SCC.
A sufficiently large proportion of the transfected DCs expressed genes specifying TAAs to induce the antitumor immune response. Cellular immunity toward KLN205 cells was induced in mice injected with the transfected cells. Since only a small proportion of the transfected cells would be expected to express TAAs, our findings that antitumor responses followed immunizations with the transfected DCs may be taken as an indication that multiple and possibly large numbers of immunologically distinct TAAs, the products of numerous altered genes, were present in the neoplastic cells.
We conclude that the transfected DCs expressed an array of undefined TAAs in a highly immunogenic form. TAAs expressed by the transfected cells were not identified. The identification of TAAs expressed by the patient's neoplasm may not be a prerequisite for the generation of a vaccine that can be used effectively in cancer therapy.
It is likely that the transfected DCs expressed predominantly nontumor-associated self-determinants. Few determinants formed by the transfected cells would be expected to be uniquely expressed by the neoplastic cells. There is a theoretical danger that an autoimmune response would be generated in mice injected with the vaccine. However, like other types of tumor vaccines, such as those prepared by ''feeding'' autologous DCs with tumor cell-lysates or by transfer of RNA from cancer cells into DCs, self-determinants were likely to be expressed in the greatest proportion. In these studies, as in our own, autoimmune reactions were not observed. The immunized mice including those that rejected the SCC survived indefinitely, without evidence of disease.
The data presented here raise the possibility that a conveniently prepared vaccine useful in the treatment of squamous carcinoma can be generated by transfection of autologous DCs with genomic DNA derived from small amounts of autologous tumor. As for other types of immunotherapeutic strategies, it is likely that treatment in combination with established cancer therapies will be required to obtain an optimum therapeutic response in patients with the disease.
